Mads Krogsgaard Thomsen
 | This article contains content that is written like an advertisement. (May 2021) |
Mads Krogsgaard Thomsen | |
|---|---|
| File:MadsKrogsgaard.jpg | |
| Born | December 27–, 1960 |
| Citizenship | Danish |
| Education | DVM, DSc and PhD |
| Employer | Novo Nordisk Foundation |
| Title | CEO of Novo Nordisk Foundation |
| Board member of | Technical University of Denmark (DTU), University of Copenhagen |
Mads Krogsgaard Thomsen (born December 27, 1960) is a Danish businessman, CEO of the Novo Nordisk Foundation[1][2][3] and former Executive Vice President of Research & Development, head of R&D and Chief Scientific Officer (CSO) at the pharmaceutical company Novo Nordisk.[4] He was appointed senior vice president of Diabetes R&D in 1994 and in November 2000 he was appointed executive vice president and chief science officer.
Mads Krogsgaard Thomsen was employed by Novo Nordisk in 1991 as head of Growth Hormone Research and became Executive Vice President for Diabetes R&D in 1994. In November 2000 he was appointed executive vice president and Chief Scientific Officer (CSO).[4] From 1994 to 2021 he was responsible for the research and development of 20 medical products especially within diabetes treatment and the groundbreaking development of GLP-1 and tablet technology used as replacement for conventional injection-based technology in biological diabetes treatment. Mads Krogsgaard Thomsen left the position as Senior Vice President o R&D on February 28 in 2021 for the position as CEO of the Novo Nordisk Foundation where he replaced Birgitte Nauntofte. He took over the role as CEO on March 1, 2021.[1]
From 2017 to 2019, Thomsen was the chairman of the board of directors at University of Copenhagen.
Education and background
Mads Krogsgaard Thomsen went to boarding school in Epsom, Surrey in Great Britain from 1967 to 1971. He graduated from highschool from Rungsted Statsskole in 1979. He holds a master's degree from The Royal Veterinary and Agricultural University from 1986, now part of the University of Copenhagen. According to Krogsgaard Thomsen himself, he originally wanted to be a practicing veterinarian, and was inspired by the British television series All Creatures Great And Small.[5] At the Royal Veterinary and Agricultural University, however, he started to take an interest in pursuing a career in either science or the pharmaceutical industry. He finished his PhD. from the same university in 1991.
Career
- 1982–1985 Instructor and assistant lecturer, University of Copenhagen
- 1986–1987 Clinical Institute PhD stipend, University of Copenhagen
- 1987–1988 Department of Pharmacology, PhD stipend, University of Copenhagen
- 1988–1991 Pharmacologist at Leo Pharma[6]
- 1991–2000 Ledership positions at Novo Nordisk, from 1994 as Senior Vice President
- 1991–1993 Head of Growth Hormone Pharmacology, Biopharmaceuticals Division, Novo Nordisk
- 1993–1994 Director of Pharmacology, Diabetes Care Division, Novo Nordisk
- 1994–1995 Senior Vice President of Diabetes Research & Development, Diabetes Care Division, Novo Nordisk
- 1995–1998 Corporate Vice President of Drug Discovery, Novo Nordisk
- 1998–2000 Corporate Vice President of Drug Discovery and Preclinical Development, Novo Nordisk
- 2000–2021 Chief Scientific Officer and Executive Vice President of Research and Development, Novo Nordisk
- 2000–Adjunct Professor of Pharmacology, University of Copenhagen[6]
- 2021–present: CEO, Novo Nordisk Foundation
Board positions
- 2000–2008 Board member, Technical University of Denmark (DTU)
- 2000–2003 Board member, Akademiet for de Tekniske Videnskaber (2002–2004 chairman)
- 2006–2012 Board member, Cellartis AB
- 2012–2019 Board member, University of Copenhagen (2017–2020 chairman)
- 2014–2016 chairman, Steno Diabetes Center
- 2018–2019 Board member, Symphogen
- 2020–present: Board member, BB Biotech
Private life
Mads Krogsgaard Thomsen is married to Ulla. They reside in Denmark and he has three children.[7]
References
- ^ a b Mostrup, Christian (February 3, 2021). "Mads Krogsgaard Thomsen appointed as new CEO of the Novo Nordisk Foundation". Novo Nordisk Fonden.
- ^ Heimer, Hakon (February 24, 2021). "Leadership Change at Novo Nordisk Foundation | Nordic Society for Precision Medicine". nshg-pm.org. Retrieved May 27, 2021.
- ^ "New CEO of the Novo Nordisk Foundation". european-biotechnology.com. February 24, 2021. Retrieved May 27, 2021.
- ^ a b "Mads Krogsgaard Thomsen". sciencenews.dk (in Danish). Retrieved May 27, 2021.
- ^ Friis, Rasmus (March 3, 2022). "Det hele faldt på plads for Mads Krogsgaard på andet semester". Uniavisen. Retrieved July 6, 2022.
{{cite web}}: CS1 maint: url-status (link) - ^ a b "Mads Krogsgaard Thomsen appointed as new CEO of the Novo Nordisk Foundation". Danish Diabetes Academy. February 4, 2021. Retrieved May 27, 2021.
- ^ Mortensen, Thomas Mikkel (October 5, 2019). "Efter ti års fejlslagen forskning fik Mads en dristig idé: Nu har Novo ramt en guldåre". Berlingske.dk (in Danish). Retrieved May 27, 2021.